您的账号已在其他设备登录,您当前账号已强迫下线,
如非您本人操作,建议您在会员中心进行密码修改

确定
收藏 | 浏览75

The oral vasopressin-2 receptor antagonist tolvaptan causes aquaresis in patients with volume overload, potentially facilitating decongestion and improving the clinical course of patients with acute heart failure (AHF).To address the acute use of tolvaptan to improve congestion in AHF, we conducted the Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure (TACTICS-HF, NCT01644331) study.TACTICS-HF randomized patients within 24 hours of AHF presentation in a prospective, double blind, placebo-controlled trial. Patients were eligible regardless of ejection fraction, and were randomized to either 30 mg of tolvaptan or placebo given at 0, 24, and 48 hours, with a fixed-dose furosemide regimen as background therapy. The primary endpoint was the proportion of patients considered responders at 24 hours. Secondary endpoints included symptom improvement, changes in renal function, and clinical events.A total of 257 patients were randomized. Dyspnea relief by Likert scale was similar between tolvaptan and placebo at 8 hours (25

作者:G Michael, Felker;Robert J, Mentz;Robert, Cole;Kirkwood F, Adams;Gregory F, Egnaczyk;Mona, Fiuzat;Chetan B, Patel;Melvin, Echols;Michel G, Khouri;James M, Tauras;Divya, Gupta;Pamela, Monds;Rhonda, Roberts;Christopher M, O'Connor

来源:Journal of the American College of Cardiology 2016 年

知识库介绍

临床诊疗知识库该平台旨在解决临床医护人员在学习、工作中对医学信息的需求,方便快速、便捷的获取实用的医学信息,辅助临床决策参考。该库包含疾病、药品、检查、指南规范、病例文献及循证文献等多种丰富权威的临床资源。

详细介绍
热门关注
免责声明:本知识库提供的有关内容等信息仅供学习参考,不代替医生的诊断和医嘱。

收藏
| 浏览:75
作者:
G Michael, Felker;Robert J, Mentz;Robert, Cole;Kirkwood F, Adams;Gregory F, Egnaczyk;Mona, Fiuzat;Chetan B, Patel;Melvin, Echols;Michel G, Khouri;James M, Tauras;Divya, Gupta;Pamela, Monds;Rhonda, Roberts;Christopher M, O'Connor
来源:
Journal of the American College of Cardiology 2016 年
标签:
acute heart failure decongestion outcomes strategies volume overload
The oral vasopressin-2 receptor antagonist tolvaptan causes aquaresis in patients with volume overload, potentially facilitating decongestion and improving the clinical course of patients with acute heart failure (AHF).To address the acute use of tolvaptan to improve congestion in AHF, we conducted the Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure (TACTICS-HF, NCT01644331) study.TACTICS-HF randomized patients within 24 hours of AHF presentation in a prospective, double blind, placebo-controlled trial. Patients were eligible regardless of ejection fraction, and were randomized to either 30 mg of tolvaptan or placebo given at 0, 24, and 48 hours, with a fixed-dose furosemide regimen as background therapy. The primary endpoint was the proportion of patients considered responders at 24 hours. Secondary endpoints included symptom improvement, changes in renal function, and clinical events.A total of 257 patients were randomized. Dyspnea relief by Likert scale was similar between tolvaptan and placebo at 8 hours (25